阿伦膦酸钠治疗绝经后骨质疏松症的疗效观察.docVIP

阿伦麟酸钠治疗绝经后骨质疏松症的疗效观察 【摘要】目的观察阿伦麟酸钠对绝经后妇女原发性骨质疏松症的有效性和安 全性。方法 绝经后骨质疏松患者130例，将患者完全随机分成观察组及对照组， 各65例。观察组每周口服阿伦麟酸钠70mg和元素钙(碳酸钙)及骨化醇；对照组 口服元素钙(碳酸钙)及骨化醇。疗程均为12个月；通过骨密度仪观察治疗前及 治疗后的骨密度的变化。结果治疗12个月后，观察组L2?4和股骨颈平均骨密 度明显高于治疗前和对照组治疗后[L2~4： (844plusmn;116) mg/cm3比 (788plusmn;76)mg/cm3 (785plusmn;64)mg/cm3；股骨颈:(681plusmn;71) mg/cm3 比(644plusmn;72) mg/cm3、(662plusmn;90) mg/cm3],差异均有 统计学意义(Plt;0.05或Plt;0.01)o治疗过程中未发现与药物有关的不良反应。 结论阿伦麟酸钠治疗绝经后骨质疏松症有效見安全。 【关键词】绝经后骨质疏松症；阿伦麟酸钠；骨矿盐密度 中图分类号R 文献标识码 Effects of alendronate on postmenopausal osteoporosis SUN jing- hua, XU Xiao-feng ,CHI Xiao-fei,WANG Jing-liang. Department of orthopedics,Dalian Sec ond Peoplersquo;s Hospital, Dalia ng 116011,Chi na Corresp on ding author:SUN Jing-hua, Email： sun jinghua790108@163.com 【Abstract 】 Objective To determine the efficiency and safety of alendronate on primary osteoporosis in postmenopausal women. Methods One hundred and thirty cases of postmenopausal women with osteoporosis were randomly divided into 2 group (control group and treatment group). All subjects in treatment group received alendronate 70 mg weekly.AII patients received supplemental calcium and alfacalcidol orally daily for 12 mon ths . Results Bone mineral den sity of L2~4 and femur neck in treatment group after treatment for 12 months were more than those before treatment and those in control group after treatment for 12 months[L2?4： (844plusmn;226) mg/cm3 (788plusmn;76) mg/cm3 (785plusmn;64) mg/cm3； neck of femur： (681plusmn;71) mg/cm3 (644plusmn;72) mg/cm3^ (662plusmn;90) mg/cm3] and there were significant differences (Plt;0.05 or Plt;0.01).During treatment, drug related adverse reactions were occurred. Conclusion Alendonate is well effective and safe at doses of 70 mg weekly in the treatment of primary osteoporosis in postmenopausal women. 【Key words] Postmenopausal osteoporosis; Alendronate;Bone mineral density 阿伦麟酸钠(ALN) [1]是-?种新型、高效的含氨基的二麟酸盐类骨吸收抑制剂。因 其具有抑制破骨细胞，降低骨转移，增加骨量，降低老年脆性骨折的发生率等作 用，已于1995年被美国食品和药物管理局(FDA)推荐为预防及治疗原发性骨 质疏松症的临床用